Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.34 |
| ▸ | JAK2 | O60674 | 4/20 | 0.34 |
| ▸ | JAK1 | P23458 | 4/20 | 0.34 |
| ▸ | TYK2 | P29597 | 4/20 | 0.34 |
| ▸ | JAK3 | P52333 | 3/20 | 0.34 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | POLQ | O75417 | 1/20 | 0.33 |
| ▸ | WNT1 | P04628 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | GPR6 | P46095 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24577300 | 1.00 | IRAK4 (0.34) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL29759832 | 0.94 | PDCD1 (0.38) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL27185212 | 0.94 | PDCD1 (0.38) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL29760053 | 0.94 | ALDH1A1 (0.37) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL29759640 | 0.93 | IRAK4 (0.35) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL27185052 | 0.93 | PDCD1 (0.38) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL24579123 | 0.93 | IRAK4 (0.35) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL29759897 | 0.93 | PDCD1 (0.38) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL30897455 | 0.92 | WNT1 (0.35) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL27185208 | 0.92 | WNT1 (0.35) | IRAK4JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109917-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2024-04-04 | — | — | US | disclosed |
| EP-4267585-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | Actelion Pharmaceuticals Ltd (CH) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022136509-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109917-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | PDGFRA, PDGFRB, ABL1 | IRAK4 1838/4885JAK2 9/4885JAK1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.